Cureety

Cureety, founded in March 2018 by François-Guirec Champoiseau and Hugo Breitwiller, is a digital health company headquartered in Dinan, France, with additional offices in Paris, Barcelona, and soon Italy. The firm operates in the onco-hematology market, providing a remote patient monitoring platform to transform cancer care from a reactive to a proactive model. Co-founder Hugo Breitwiller's background includes four years of developing a software and design-focused weight loss and wellness application, an experience that equipped him with the skills to address user needs in the complex medical software landscape of oncology. This prior venture informed his approach at Cureety, where he focuses on translating patient and caregiver requirements into a simple and effective software solution.

The company's core offering is the Cureety TechCare platform, a Class IIa medical device under EU regulations. This software-as-a-medical-device (SaaMD) enables healthcare professionals to monitor patients remotely between consultations. Patients use a mobile or web application to complete personalized questionnaires based on their specific treatment protocols, reporting symptoms and side effects. The platform utilizes proprietary clinical algorithms, based on the Common Terminology Criteria for Adverse Events (CTCAE), to analyze patient-reported outcomes. Based on this analysis, the system generates alerts for clinical teams, helping them prioritize care for patients whose conditions have significantly deteriorated. This allows for earlier intervention, aiming to reduce emergency hospitalizations and improve patient quality of life. The platform supports a wide range of treatments, including chemotherapy, immunotherapy, targeted therapy, and radiotherapy.

Cureety's business model is multifaceted, generating revenue through the deployment of its platform in healthcare institutions and by engaging in research partnerships. Its clients are primarily healthcare providers, such as hospitals and cancer centers, with the platform being used in over 170 institutions across France, Spain, and Italy. The company has established a pan-European network of providers and research institutions. Furthermore, Cureety collaborates with pharmaceutical companies like AstraZeneca, Servier, and Ipsen to accelerate platform deployment and support clinical research programs. The platform's ability to collect real-world data on treatment side effects and patient quality of life creates a valuable dataset for advancing cancer research. In a significant milestone, the French National Authority for Health approved Cureety as the first oncology remote patient monitoring platform to be reimbursed by the national statutory insurance.

Keywords: remote patient monitoring, oncology, digital health, cancer care, healthtech, real-world data, patient-reported outcomes, medical software, clinical algorithms, telemonitoring, onco-hematology, chemotherapy side effect management, radiotherapy support, clinical research data, digital therapeutics, healthcare software, patient engagement, proactive care, medical device software, supportive care